Research programme: neurin-based anticancer therapy - Novo NordiskAlternative Names: NNC 47-0011
Latest Information Update: 25 Sep 2006
At a glance
- Originator Novo Nordisk
- Mechanism of Action Protein tyrosine kinase inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 25 Sep 2006 Discontinued - Preclinical for Cancer in Sweden (unspecified route)
- 25 Sep 2006 Discontinued - Preclinical for Cancer in Denmark (unspecified route)
- 09 Oct 2003 Preclinical trials in Cancer in Sweden (unspecified route)